Hsbc Holdings PLC Makes New Investment in Bruker Corporation $BRKR

Hsbc Holdings PLC purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, HoldingsChannel reports. The firm purchased 88,647 shares of the medical research company’s stock, valued at approximately $5,252,000.

A number of other hedge funds have also modified their holdings of BRKR. Orbis Allan Gray Ltd boosted its position in Bruker by 5.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after buying an additional 761,258 shares during the last quarter. Pallas Capital Advisors LLC purchased a new position in Bruker during the 2nd quarter worth approximately $570,746,000. State Street Corp lifted its stake in Bruker by 2.5% during the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after acquiring an additional 91,706 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the last quarter. Finally, Sculptor Capital LP boosted its holdings in shares of Bruker by 9.0% in the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after acquiring an additional 270,000 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $57.08 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The stock has a market capitalization of $8.70 billion, a price-to-earnings ratio of -81.54, a PEG ratio of 1.81 and a beta of 1.28. The firm’s 50 day simple moving average is $58.77 and its 200-day simple moving average is $48.00. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $65.30.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. During the same period in the previous year, the business posted $0.32 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is presently -28.57%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BRKR. TD Cowen reiterated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Citigroup lowered their price target on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. Wolfe Research assumed coverage on Bruker in a research report on Monday, June 1st. They set a “peer perform” rating on the stock. Stifel Nicolaus set a $50.00 price target on Bruker in a research report on Wednesday, August 5th. Finally, Barclays lifted their price objective on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Bruker currently has a consensus rating of “Moderate Buy” and an average target price of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.